Eu­ro­pean drug reg­u­la­tor seeks to ‘stream­line’ biosim­i­lar ap­proval process

The Eu­ro­pean Med­i­cines Agency is look­ing to sim­pli­fy the way it ap­proves biosim­i­lars by re­mov­ing the need for “ex­ten­sive” clin­i­cal da­ta, which would like­ly cut …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER